Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study

Blood

Volumn 99, Issue 10, 2002, Pages 3554-3561

  Keating, Michael J ^{a,b,c,d,e,f,g,h,i}   Flinn, Ian ^{a,b,c,d,e,f,g,h,i}   Jain, Vinay ^{a,b,c,d,e,f,g,h,i}   Binet, Jacques Louis ^{a,b,c,d,e,f,g,h,i}   Hillmen, Peter ^{a,b,c,d,e,f,g,h,i}   Byrd, John ^{a,b,c,d,e,f,g,h,i}   Albitar, Maher ^{a,b,c,d,e,f,g,h,i}   Brettman, Lee ^{a,b,c,d,e,f,g,h,i}   Santabarbara, Pedro ^{a,b,c,d,e,f,g,h,i}   Wacker, Bret ^{a,b,c,d,e,f,g,h,i}   Rai, Kanti R ^{a,b,c,d,e,f,g,h,i}  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c TEXAS ONCOLOGY   (United States)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e LEEDS GENERAL INFIRMARY   (United Kingdom)

^f OHIO STATE UNIVERSITY   (United States)

^g MILLENNIUM PHARMACEUTICALS INC   (United States)

^h Ilex Oncology   (United States)

ⁱ LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; ETOPOSIDE; FLUDARABINE; MITOXANTRONE; PARACETAMOL; PREDNISONE;

ADULT; AGED; ARTICLE; B CELL LEUKEMIA; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFECTION; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0037092951     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.10.3554     Document Type: Article

References (28)

1. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer
2. Results of first salvage therapy for patients refractory to a Fludara regimen in chronic lymphocytic leukemia
3. Treatment of chronic lymphocytic leukaemia. French Co-operative Group on CLL
4. Fludarabine monophosphate: A potentially useful agent in chronic lymphocytic leukemia
5. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy
6. The Scripps Clinic experience with cladribine (2-CdA) in the treatment of chronic lymphocytic leukemia
7. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL
8. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia
9. Activity of fludarabine in refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma - The Jerusalem experience
10. Salvage therapy with fludarabine in patients with progressive B-chronic lymphocytic leukemia
11. Fludarabine treatment in B-cell chronic lymphocytic leukemia: Response, toxicity and survival analysis in 47 cases
12. Primary structure of CD52
13. Effect of Campath-1H antibody on human hemaiopoietic progenitors in vitro
14. Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation
15. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype
16. Structural motifs involved in human IgG antibody effector functions
17. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells
18. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia
19. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment
20. Non-parametric estimation from incomplete observations
21. Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: A phase II study
22. Analysis of response to Campath-1H in patients with B-CLL progressing after fludarabine therapy
23. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia
24. Rituximab dose-escalation trial in chronic lymphocytic leukemia
25. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity
26. Campath-1H and fludarabine in combination is highly active in refractory CLL
27. CAMPATH-1H therapy of patients with previously untreated chronic lymphocytic leukemia (CLL)